

APPROVED PROFESSIONAL INFORMATION

SCHEDULING STATUS

S3

1. NAME OF THE MEDICINE

INDAPAMIDE 1.5 mg SR PD sustained release tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each sustained release tablet contains 1.5 mg Indapamide.

INDAPAMIDE 1.5 mg SR PD contains sugar (lactose monohydrate 91,125 mg per tablet).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Sustained release tablets.

The product appears as white, round, slightly biconvex film coated tablets.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

INDAPAMIDE 1.5 mg SR PD is indicated in the management of mild to moderate hypertension.

APPROVED PROFESSIONAL INFORMATION

4.2 Posology and method of administration

Posology

Adults: One tablet daily, to be swallowed whole with water and not chewed, preferably taken on arising in the morning.

INDAPAMIDE 1.5 mg SR PD (1.5 mg indapamide) can be combined with other categories of antihypertensive agents, in more severe cases.

The antihypertensive action of indapamide is not enhanced at higher doses, but the saluretic effect is increased.

Special populations

Renal impairment

In severe renal failure (creatinine clearance below 30 mL/min), treatment is contraindicated (see section 4.3).

Thiazide and related diuretics are fully effective only when renal function is normal or only minimally impaired (see section 4.4).

Hepatic impairment

In severe hepatic impairment, treatment is contraindicated (see sections 4.3 and 4.4).

Elderly

In the elderly, the plasma creatinine must be adjusted in relation to age, weight and gender.

Elderly patients can be treated with INDAPAMIDE 1.5 mg SR PD when renal function is normal or only minimally impaired (see section 4.4).

APPROVED PROFESSIONAL INFORMATION

Paediatric population

Safety and efficacy have not been established and INDAPAMIDE 1.5 mg SR PD is not recommended for use in children and adolescents under the age of 18 years as no data are available.

Method of administration

Oral use.

4.3 Contraindications

- hypersensitivity to indapamide, other sulphonamide type medications, or to any of the ingredients of INDAPAMIDE 1.5 mg SR PD
- hepatic encephalopathy or severe hepatic impairment
- in patients with severe renal failure
- in patients with hypokalaemia.

4.4 Special warnings and precautions for use

The elderly patient population may be more sensitive to the electrolyte and hypotensive effects of INDAPAMIDE 1.5 mg SR PD. In addition, elderly patients are more likely to have renal function impairment, which may require caution. The following medical conditions should be considered for risk-benefit when present in patients: severe renal impairment or anuria, history of gout, diabetes mellitus, hyperuricaemia, hepatic impairment and sympathectomy.

APPROVED PROFESSIONAL INFORMATION

Hypersensitivity to other sulphonamide-type medicines may lead to allergic reaction when taking INDAPAMIDE 1.5 mg SR PD.

Laboratory test values that may be altered while taking INDAPAMIDE 1.5 mg SR PD include the following: calcium and protein-bound iodine (decreased); plasma renin activity (increased); potassium and sodium (decreased, but within normal limits); uric acid (increased, but within normal limits).

Special warnings

When liver function is impaired, thiazide-related diuretics may cause hepatic encephalopathy, particularly in case of electrolyte imbalance. Administration of the diuretic must be stopped immediately if this occurs.

Photosensitivity

Cases of photosensitivity reactions have been reported with thiazides and thiazide-related diuretics (see section 4.8). If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a re-administration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.

Special precautions for use

Water and electrolyte balance

Plasma sodium:

This must be measured before starting treatment, then at regular intervals subsequently. The fall in plasma sodium may be asymptomatic initially and regular monitoring is therefore essential. Monitoring should be even more frequent in the elderly and cirrhotic patients (see sections 4.8

APPROVED PROFESSIONAL INFORMATION

and 4.9). Any diuretic treatment may cause hyponatraemia, sometimes with very serious consequences.

Hyponatraemia with hypovolaemia may be responsible of dehydration and orthostatic hypotension.

Concomitant loss of chloride ions may lead to secondary compensatory metabolic alkalosis: the incidence and degree of this effect are slight.

Plasma potassium:

Potassium depletion with hypokalaemia is the major risk of thiazide and related diuretics. The risk of onset of hypokalaemia (< 3,4 mmol/L) must be prevented in certain high-risk populations, i.e. the elderly, malnourished and/or polymedicated, cirrhotic patients with oedema and ascites, coronary artery disease and cardiac failure patients. In this situation, hypokalaemia increases the cardiac toxicity of digitalis preparations and the risks of arrhythmias.

Individuals with a long QT interval are also at risk, whether the origin is congenital or iatrogenic. Hypokalaemia, as well as bradycardia, is then a predisposing factor to the onset of severe arrhythmias, in particular, potentially fatal *torsades de pointes*.

More frequent monitoring of plasma potassium is required in all the situations indicated above. The first measurement of plasma potassium should be obtained during the first week following the start of treatment.

Detection of hypokalaemia requires its correction.

In patients at risk of developing hypokalaemia, serum potassium should be monitored, and they may require potassium supplements or potassium-sparing diuretics.

Co-administration of INDAPAMIDE 1.5 mg SR PD with other diuretics, which may cause hypokalaemia, is not recommended (see section 4.5).

APPROVED PROFESSIONAL INFORMATION

Hypokalaemia found in association with low serum magnesium concentration can be refractory to treatment unless serum magnesium is corrected.

Plasma magnesium:

Thiazides and related diuretics including indapamide have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia (see section 4.5 and 4.8).

Plasma calcium:

Thiazide and related diuretics may decrease urinary calcium excretion and cause a slight and transitory rise in plasma calcium. Frankly, hypercalcaemia may be due to previously unrecognized hyperparathyroidism.

Treatment should be withdrawn before the investigation of parathyroid function.

Uric acid:

Concentrations of serum uric acid should be monitored particularly in patients with a history of gout, who should continue with appropriate treatment.

Mild to moderately impaired renal function:

INDAPAMIDE 1.5 mg SR PD can be administered to hypertensive patients with mild to moderately impaired renal function. If azotaemia or oliguria occurs, the treatment should be discontinued.

Blood glucose:

Monitoring of blood glucose is important in diabetics, in particular in the presence of hypokalaemia.

Renal function and diuretics:

Thiazide and related diuretics are fully effective only when renal function is normal or only minimally impaired (plasma creatinine below levels of the order of 25 mg/L, i.e. 220 µmol/L in an

APPROVED PROFESSIONAL INFORMATION

adult). In the elderly, this plasma creatinine must be adjusted in relation to age, weight and gender.

Hypovolaemia, secondary to the loss of water and sodium induced by the diuretic at the start of treatment causes a reduction in glomerular filtration. This may lead to an increase in blood urea and plasma creatinine. This transitory functional renal insufficiency is of no consequence in individuals with normal renal function but may worsen pre-existing renal insufficiency.

Athletes:

The attention of athletes is drawn to the fact that this medicinal product contains a drug substance, which may give a positive reaction in doping tests.

Choroidal effusion, acute myopia and secondary angle-closure glaucoma:

Sulfonamide, or sulfonamide derivativemedicines, can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue medicine intake as rapidly as possible. Promptmedical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.

Excipients:

INDAPAMIDE 1.5 mg SR PD contains sugar (lactose monohydrate 91,125 mg per tablet).

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Patients with rare hereditary

APPROVED PROFESSIONAL INFORMATION

problems of galactose intolerance e.g. galactasaemia, Lapp lactase deficiency, or glucose-galactose malabsorption or fructose intolerance should not take INDAPAMIDE 1.5 mg SR PD. Lactose may have an effect on the glycaemic control of patients with diabetes mellitus.

Paediatric population

Children: Safety and efficacy have not been established, and INDAPAMIDE 1.5 mg SR PD is not recommended for use in children (see section 4.2).

4.5 Interaction with other medicines and other forms of interaction

Combinations that are not recommended:

Lithium

Increased plasma lithium with signs of overdosage, as with a salt-free diet (decreased urinary lithium excretion). However, if the use of diuretics is necessary, careful monitoring of plasma lithium and dose adjustment are required.

Combinations requiring precautions for use:

Torsades de pointes-inducing medicines

- class Ia antiarrhythmics (quinidine, hydroquinidine, disopyramide),
- class III antiarrhythmics (amiodarone, sotalol, dofetilide, ibutilide),
- some antipsychotics: phenothiazines (chlorpromazine, cyamemazine, levomepromazine, thioridazine, trifluoperazine), benzamides (amisulpride, sulpiride, sultopride, tiapride) and butyrophenones (droperidol, haloperidol)
- others: bepridil, cisapride, diphemanil, erythromycin IV, halofantrine, mizolastine,

APPROVED PROFESSIONAL INFORMATION

pentamidine, sparfloxacin, moxifloxacin, vincamine IV.

Increased risk of ventricular arrhythmias, particularly *torsades de pointes* (hypokalaemia is a risk factor).

Monitor for hypokalaemia and correct, if required, before introducing this combination.

Clinical, plasma electrolytes and ECG monitoring.

Use substances which do not have the disadvantage of causing *torsades de pointes* in the presence of hypokalaemia.

N.S.A.I.Ds. (systemic route) including COX-2 selective inhibitors, high dose salicylic acid (≥ 3 g/day)

Possible reduction in the antihypertensive effect of indapamide.

Risk of acute renal failure in dehydrated patients (decreased glomerular filtration). Hydrate the patient; monitor renal function at the start of treatment.

Angiotensin converting enzyme (A.C.E) inhibitors

Risk of sudden hypotension and/or acute renal failure when treatment with an ACE inhibitor is initiated in the presence of pre-existing sodium depletion (particularly in patients with renal artery stenosis).

In hypertension, when prior diuretic treatment may have caused sodium depletion, it is necessary:

- either to stop the diuretic 3 days before starting treatment with the ACE inhibitor, and restart with a hypokalaemic diuretic if necessary;
- or give a low initial dose of the ACE inhibitor and increase the dose gradually.

In congestive heart failure, start with a very low dose of ACE inhibitor, possibly after a reduction in the dose of the concomitant hypokalaemic diuretic.

APPROVED PROFESSIONAL INFORMATION

In all cases, monitor renal function (plasma creatinine) during the first weeks of treatment with an ACE inhibitor.

Other compounds causing hypokalaemia: amphotericin B (IV), gluco- and mineralo-corticoids (systemic route), tetracosactide, stimulant laxatives

Increased risk of hypokalaemia (additive effect).

Monitoring of plasma potassium and correction if required. Must be particularly borne in mind in the case of concomitant digoxin treatment and in the use of non-stimulant laxatives.

Baclofen

Increased antihypertensive effect.

Hydrate the patient; monitor renal function at the start of treatment.

Digoxin

Hypokalaemia predisposing to the toxic effects of digoxin.

Monitoring of plasma potassium and ECG and, if necessary, adjust the treatment.

Combinations requiring special care:

Allopurinol

Concomitant treatment with indapamide may increase the incidence of hypersensitivity reactions to allopurinol.

Combinations to be taken into consideration:

Potassium-sparing diuretics (amiloride, spironolactone, triamterene)

Whilst rational combinations are useful in some patients, hypokalaemia or hyperkalaemia (particularly in patients with renal failure or diabetes) may still occur. Plasma potassium and

APPROVED PROFESSIONAL INFORMATION

ECG should be monitored and, if necessary, treatment reviewed.

Metformin

Increased risk of metformin induced lactic acidosis due to the possibility of functional renal failure associated with diuretics and more particularly with loop diuretics. Do not use metformin when plasma creatinine exceeds 15 mg/L (135 µmol/L) in men and 12 mg/L (110 µmol/L) in women.

Iodinated contrast media

In the presence of dehydration caused by diuretics, increased risk of acute renal failure, in particular when large doses of iodinated contrast media are used. Rehydration before administration of the iodinated compound.

Imipramine-like antidepressants, neuroleptics

Antihypertensive effect and increased risk of orthostatic hypotension increased (additive effect).

Calcium (salts)

Risk of hypercalcaemia resulting from decreased urinary elimination of calcium.

Ciclosporin, tacrolimus

Risk of increased plasma creatinine without any change in circulating cyclosporin levels, even in the absence of water/sodium depletion.

Corticosteroids, tetracosactide (systemic route)

Decreased antihypertensive effect (water/sodium retention due to corticosteroids).

Paediatric population

Children: Safety and efficacy have not been established, and INDAPAMIDE 1.5 mg SR PD is not recommended for use in children.

APPROVED PROFESSIONAL INFORMATION

4.6 Fertility, pregnancy and lactation

Women of childbearing potential / Contraception in males and females

Reproductive toxicity studies showed no effect on fertility in female and male rats (see section 5.3). No effects on human fertility are anticipated.

Pregnancy

INDAPAMIDE 1.5 mg SR PD

INDAPAMIDE 1.5 mg SR PD should be avoided in pregnant women and should never be used to treat physiological oedema of pregnancy. Diuretics can cause foeto-placental ischaemia, with a risk of impaired foetal growth.

Breastfeeding

INDAPAMIDE 1.5 mg SR PD treatment is not recommended during breastfeeding. There is insufficient information on the excretion of indapamide/metabolites in human milk.

Hypersensitivity to sulphonamide-derived medicines and hypokalaemia might occur. A risk to the newborns/infants cannot be excluded.

Indapamide is closely related to thiazide diuretics which have been associated with decrease or even suppression of milk lactation, during breast-feeding.

Fertility

Reproductive toxicity studies showed no effect on fertility in female and male rats. No effects on human fertility are anticipated.

APPROVED PROFESSIONAL INFORMATION

4.7 Effects on ability to drive and use machines

INDAPAMIDE 1.5 mg SR PD does not affect alertness but different reactions in relation to the decrease in blood pressure may occur in individual cases, especially at the start of the treatment or when another antihypertensive agent is added.

As a result, the ability to drive vehicles or to operate machinery may be impaired.

4.8 Undesirable effects

a. Summary of the safety profile

The most commonly reported adverse reactions are hypersensitivity reactions, mainly dermatological, in subjects with a predisposition to allergic and asthmatic reactions and maculopapular rashes.

During clinical trials, hypokalaemia (plasma potassium <3,4 mmol/L) was seen in 10 % of patients and < 3.2 mmol/L in 4 % of patients after 4 to 6 weeks treatment. After 12 weeks treatment, the mean fall in plasma potassium was 0,23 mmol/L.

The majority of adverse reactions concerning clinical or laboratory parameters are dose-dependent.

APPROVED PROFESSIONAL INFORMATION

b. Tabulated list of adverse effects

System Organ Class	Frequency	Side effects
Blood and lymphatic system disorders	Less frequent	Thrombocytopaenia, granulocytopaenia, leucopaenia, aplastic anaemia, haemolytic anaemia, hypochloraemic alkalosis, hyponatraemia, hypokalaemia, hyperuricaemia
Immune system disorders	Less frequent	Skin rash, itching, pulmonary oedema, pneumonitis, cholestatic jaundice
Metabolism and nutrition disorders	Less frequent Frequency unknown	Hypercalcaemia Potassium depletion with hypokalaemia, particularly serious in certain high-risk populations (see section 4.4) hyponatraemia (see section 4.4)
Nervous system disorders	Less frequent Frequency unknown	Headaches, postural hypotension (dizziness especially when standing up from lying or sitting position), fatigue, paraesthesia Syncope
Eye disorders	Frequency unknown	Myopia, blurred vision, visual impairment, choroidal effusion
Cardiac disorders	Less frequent Frequency unknown	Arrhythmia <i>Torsade de pointes</i> (potentially fatal) (see sections 4.4 and 4.5)
Vascular disorders	Less frequent	Hypotension

APPROVED PROFESSIONAL INFORMATION

Gastrointestinal disorders	Less frequent	Anorexia, gastric irritation, nausea, vomiting, constipation, diarrhoea, dry mouth, pancreatitis
Hepatobiliary disorders	Less frequent Frequency unknown	Abnormal hepatic function, Possibility of onset of hepatic encephalopathy in case of hepatic insufficiency (see sections 4.3 and 4.4), hepatitis
Skin and subcutaneous tissue disorders	Frequent Less frequent Frequency unknown	Hypersensitivity reactions, maculopapular rashes Purpura, angioedema, urticaria, Toxic epidermic necrolysis, Stevens-Johnson Syndrome Possible worsening of pre-existing acute disseminated lupus erythematosus, photosensitivity reactions (see section 4.4)
Musculoskeletal, connective tissue and bone disorders	Frequency unknown	Muscle spasms, muscular weakness, myalgia, rhabdomyolysis
Renal and urinary disorders	Less frequent	Renal failure
Reproductive system and breast disorders	Less frequent	Erectile dysfunction
Investigations	Frequency unknown	Electrocardiogram QT prolonged (see sections 4.4 and 4.5), blood glucose increased (see section 4.4), blood uric acid increased (see section 4.4), elevated liver enzyme levels

APPROVED PROFESSIONAL INFORMATION

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are requested to report any suspected adverse drug reactions to SAHPRA via the Med Safety APP (Medsafety X SAHPRA) and eReporting platform (who-umc.org) found on SAHPRA website.

An email can be sent directly to the company, pharmacovigilance@pharmadynamics.co.za, to ensure safety of the product.

4.9 Overdose

Indapamide has been found free of toxicity at up to 40 mg. This is 27 times the therapeutic dose.

Signs and symptoms:

Signs of acute poisoning take the form above all of water/electrolyte disturbances (hyponatraemia, hypokalaemia). Clinically, possibility of nausea, vomiting, hypotension, cramps, vertigo, drowsiness, confusion, polyuria or oliguria possibly to the point of anuria (by hypovolaemia).

Management of overdose:

INDAPAMIDE 1.5 mg SR PD

Initial measures involve the rapid elimination of the ingested substance(s) by gastric wash-out and/or administration of activated charcoal, followed by restoration of water/electrolyte balance to normal in a specialised centre.

APPROVED PROFESSIONAL INFORMATION

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Sulfonamides, plain

ATC code: C 03 BA 11

Pharmacological classification: A 7.1 Vasodilators, Hypotensive Medicine.

Mechanism of action

Indapamide, [N-(3-sulphamoyl-4-chlorobenzamido) 2-methyl indoline], exhibits an antihypertensive action and falls in the chemical indole type of chlorosulphonamide. The antihypertensive effect of indapamide is due to the reduction in the total peripheral and arterial vascular resistance and possibly involves both renal and extra-renal effects. The diuretic effect (reduction of extra-cellular and blood volume) is believed to contribute minimally as decreases in blood pressure occur at doses well below the effective diuretic dose of indapamide.

Hypertensive patients on long term indapamide treatment experience a reduction in left ventricular mass.

The elimination half-life is 14 -18 hours. Indapamide has a high plasma protein binding between 71 % and 79 %. The methyl-indoline portion of the molecule gives indapamide its lipophilic character, and indapamide's lipid solubility is 5 - 8 times that of the thiazides. As a result of this characteristic, indapamide further binds to elastin in vascular smooth muscle.

5.2 Pharmacokinetic properties

Indapamide 1.5 mg is supplied in a sustained release dosage based on a matrix system in which indapamide is dispersed within a support which allows sustained release of indapamide.

APPROVED PROFESSIONAL INFORMATION

Absorption:

The fraction of indapamide released is rapidly and totally absorbed via the gastrointestinal digestive tract.

Eating slightly increases the rapidity of absorption but has no influence on the amount of the medicine absorbed.

Indapamide is completely absorbed reaching peak serum concentration within 12 hours, repeated administration reduces the variation in serum levels between 2 doses. Intra-individual variability exists.

Distribution:

Binding of indapamide to plasma proteins is 79 %. The plasma elimination half-life is 14 - 24 hours (mean 18 hours). Steady state is achieved after 7 days. Repeated administration does not lead to accumulation.

Biotransformation:

Indapamide is extensively metabolised in the liver and primarily renally excreted (60 - 70 %), with only 5 - 7 % found unchanged in the urine.

Elimination:

The excretion of indapamide further involves the faeces (16 - 23 %).

Pharmacokinetics in special patient groups

High risk individuals:

APPROVED PROFESSIONAL INFORMATION

Pharmacokinetic parameters are unchanged in renal failure patients.

Paediatric population

Children: Safety and efficacy have not been established and INDAPAMIDE 1.5 mg SR PD is not recommended for use in children.

5.3 Preclinical safety data

Indapamide has been tested negative concerning mutagenic and carcinogenic properties.

The highest doses administered orally to different animal species (40 - 8000 times the therapeutic dose) have shown an exacerbation of the diuretic properties of indapamide. The major symptoms of poisoning during acute toxicity studies with indapamide administered intravenously or intraperitoneally were related to the pharmacological action of indapamide, i.e. bradypnoea and peripheral vasodilation. Reproductive toxicity studies have not shown embryotoxicity and teratogenicity. Fertility was not impaired either in male or in female rats.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet cores:

Cellactose (a combination of alpha-lactose monohydrate and cellulose powder)

Hypromellose

Silica, colloidal anhydrous

Magnesium stearate

APPROVED PROFESSIONAL INFORMATION

Film coating Agent:

Opadry Y-1-7000 (a combination of hypromellose, macrogol 400 and titanium dioxide).

6.2 Incompatibilities

Not applicable

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Store at or below 30 °C.

Do not remove the blisters from the outer carton until required for use.

6.5 Nature and contents of container

INDAPAMIDE 1.5 mg SR PD tablets are packed in aluminium foil and transparent, hard PVC/PVDC foil blister strips of 3 x 10 tablets inside an outer carton box.

6.6 Special precautions for disposal

No special requirements

7. HOLDER OF THE CERTIFICATE OF REGISTRATION

Pharma Dynamics (Pty) Ltd

1st Floor, Grapevine House, Steenberg Office Park

INDAPAMIDE 1.5 mg SR PD

Pharma Dynamics (Pty) Ltd

APPROVED PROFESSIONAL INFORMATION

Silverwood Close

Westlake, Cape Town

7945, South Africa

Tel: 0860-PHARMA (742 762)/+2721 707 7000

8. REGISTRATION NUMBER(S)

A42/7.1/0790

9. DATE OF FIRST AUTHORISATION

25 November 2011

10. DATE OF REVISION OF THE TEXT

28 January 2025

NAM:

NS2 12/7.1/0138